No News is Good News for IntelliPharmaCeutics International Inc. (IPCI)
Toronto, Canada-based Intellipharmaceutics International, Inc. released news this morning to report that it has not received any notification, as provided for under the Hatch-Waxman Act, of any patent infringement proceedings by Wyeth Pharmaceuticals, the brand owner of Protonix® and wholly-owned subsidiary of Pfizer, Inc. (NYSE:PFE), for its application to bring to market a generic version of Protonix® (delayed-release pantoprazole sodium) tablets. Intellipharmaceutics announced in October 2010 that the FDA had accepted for filing its Abbreviated New Drug Application (ANDA) for its generic version of Protonix®. Per ANDA protocol, Intellipharmaceutics informed Wyeth that it had submitted paragraph IV certifications of invalidity…